These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 33191277)

  • 1. Relationship Between Depression and Disease Activity in United States Veterans With Early Rheumatoid Arthritis Receiving Methotrexate.
    Rathbun AM; England BR; Mikuls TR; Ryan AS; Barton JL; Shardell MD; Hochberg MC
    J Rheumatol; 2021 Jun; 48(6):813-820. PubMed ID: 33191277
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Merging Veterans Affairs rheumatoid arthritis registry and pharmacy data to assess methotrexate adherence and disease activity in clinical practice.
    Cannon GW; Mikuls TR; Hayden CL; Ying J; Curtis JR; Reimold AM; Caplan L; Kerr GS; Richards JS; Johnson DS; Sauer BC
    Arthritis Care Res (Hoboken); 2011 Dec; 63(12):1680-90. PubMed ID: 21905260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic lung disease in U.S. Veterans with rheumatoid arthritis and the impact on survival.
    England BR; Sayles H; Michaud K; Thiele GM; Poole JA; Caplan L; Sauer BC; Cannon GW; Reimold A; Kerr GS; Baker JF; Mikuls TR
    Clin Rheumatol; 2018 Nov; 37(11):2907-2915. PubMed ID: 30280369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular events are not associated with MTHFR polymorphisms, but are associated with methotrexate use and traditional risk factors in US veterans with rheumatoid arthritis.
    Davis LA; Cannon GW; Pointer LF; Haverhals LM; Wolff RK; Mikuls TR; Reimold AM; Kerr GS; Richards JS; Johnson DS; Valuck R; Prochazka A; Caplan L
    J Rheumatol; 2013 Jun; 40(6):809-17. PubMed ID: 23547211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Persistence With Conventional Triple Therapy Versus a Tumor Necrosis Factor Inhibitor and Methotrexate in US Veterans With Rheumatoid Arthritis.
    Sauer BC; Teng CC; Tang D; Leng J; Curtis JR; Mikuls TR; Harrison DJ; Cannon GW
    Arthritis Care Res (Hoboken); 2017 Mar; 69(3):313-322. PubMed ID: 27273801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews.
    Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Ma M; Walker D; Heslin M; Patel A; Kingsley G
    Health Technol Assess; 2014 Oct; 18(66):i-xxiv, 1-164. PubMed ID: 25351370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cotreatment with methotrexate in routine care patients with rheumatoid arthritis receiving biological treatment yields better outcomes over time.
    Boone NW; Sepriano A; van der Kuy PH; Janknegt R; Peeters R; Landewé RBM
    RMD Open; 2019; 5(1):e000836. PubMed ID: 30740244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.
    Moreland LW; O'Dell JR; Paulus HE; Curtis JR; Bathon JM; St Clair EW; Bridges SL; Zhang J; McVie T; Howard G; van der Heijde D; Cofield SS;
    Arthritis Rheum; 2012 Sep; 64(9):2824-35. PubMed ID: 22508468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression.
    Atsumi T; Yamamoto K; Takeuchi T; Yamanaka H; Ishiguro N; Tanaka Y; Eguchi K; Watanabe A; Origasa H; Yasuda S; Yamanishi Y; Kita Y; Matsubara T; Iwamoto M; Shoji T; Okada T; van der Heijde D; Miyasaka N; Koike T
    Ann Rheum Dis; 2016 Jan; 75(1):75-83. PubMed ID: 26139005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Meta-Regression of a Dose-Response Relationship of Methotrexate in Mono- and Combination Therapy in Disease-Modifying Antirheumatic Drug-Naive Early Rheumatoid Arthritis Patients.
    Bergstra SA; Allaart CF; Stijnen T; Landewé RBM
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1473-1483. PubMed ID: 27992656
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: A retrospective analysis of real-world data from the St. Gallen cohort.
    Müller RB; von Kempis J; Haile SR; Schiff MH
    Semin Arthritis Rheum; 2015 Aug; 45(1):28-34. PubMed ID: 25895697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abatacept plus methotrexate provides incremental clinical benefits versus methotrexate alone in methotrexate-naive patients with early rheumatoid arthritis who achieve radiographic nonprogression.
    Wells AF; Westhovens R; Reed DM; Fanti L; Becker JC; Covucci A; Keystone EC
    J Rheumatol; 2011 Nov; 38(11):2362-8. PubMed ID: 21885491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Open-label observation of addition of etanercept versus a conventional disease-modifying antirheumatic drug in subjects with active rheumatoid arthritis despite methotrexate therapy in the Latin American region.
    Machado DA; Guzman RM; Xavier RM; Simon JA; Mele L; Pedersen R; Ferdousi T; Koenig AS; Kotak S; Vlahos B
    J Clin Rheumatol; 2014 Jan; 20(1):25-33. PubMed ID: 24356474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Similar short-term clinical response to high-dose versus low-dose methotrexate in monotherapy and combination therapy in patients with rheumatoid arthritis.
    Bergstra SA; Allaart CF; van den Berg R; Chopra A; Govind N; Huizinga TWJ; Landewe RBM
    Arthritis Res Ther; 2017 Nov; 19(1):258. PubMed ID: 29166919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.
    O'Dell JR; Curtis JR; Mikuls TR; Cofield SS; Bridges SL; Ranganath VK; Moreland LW;
    Arthritis Rheum; 2013 Aug; 65(8):1985-94. PubMed ID: 23686414
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-adherence to methotrexate was associated with high disease activity and poor health-related outcomes during a 4-year follow-up of rheumatoid arthritis patients.
    Kang JH; Choi SE; Xu H; Park DJ; Lee JK; Lee SS
    Clin Exp Rheumatol; 2022 Sep; 40(9):1744-1753. PubMed ID: 35200117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When to adjust therapy in patients with rheumatoid arthritis after initiation of etanercept plus methotrexate or methotrexate alone: findings from a randomized study (COMET).
    Dougados MR; van der Heijde DM; Brault Y; Koenig AS; Logeart IS
    J Rheumatol; 2014 Oct; 41(10):1922-34. PubMed ID: 25128520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
    Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
    Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.
    Bykerk VP; Burmester GR; Combe BG; Furst DE; Huizinga TWJ; Ahmad HA; Emery P
    Rheumatol Int; 2018 Dec; 38(12):2225-2231. PubMed ID: 30341453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of methotrexate and low-dose prednisolone on adiponectine levels and insulin resistance in patients with rheumatoid arthritis naïve to disease-modifying antirheumatic drugs.
    Yaşar Bilge NŞ; Kaşifoğlu N; Kaşifoğlu T; Şahin F; Gönüllü E; Korkmaz C
    Int J Rheum Dis; 2016 Jul; 19(7):665-71. PubMed ID: 26222244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.